指南与共识腹部US

一种用于推荐直接抗病毒药物治疗后肝细胞癌计划性超声监测的简易评分:多中心分析

Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis.
指南 / 共识 · J Gastroenterol Hepatol · 2018-07-29

本研究基于两个地区共1069例直接抗病毒药物治疗后获得持续病毒学应答(SVR24)且无肝细胞癌病史的丙型肝炎患者,回顾性构建并验证了ADRES评分(男性、FIB-4指数>3.25、甲胎蛋白>5.0 ng/mL各计分),用于预测SVR24后肝细胞癌的发生风险。训练集和验证集的c-index分别为0.835和0.899。

要点

  • ADRES评分由男性、FIB-4指数>3.25、甲胎蛋白>5.0 ng/mL三项构成,总分0-3分。
  • 训练集中评分0、1、2、3分的2年肝细胞癌累积发生率分别为0.0%、2.1%、15.9%、28.1%。
  • 验证集中评分0、1、2、3分的2年肝细胞癌累积发生率分别为0.0%、0.7%、10.6%、未报告。

核心结论

  • ADRES评分简单易用,可能有助于预测直接抗病毒药物治疗后达到SVR24短期内肝细胞癌的发生风险。

研究设计与样本

  • 回顾性多中心分析,纳入2014年10月至2017年12月两个地区共1069例直接抗病毒药物治疗后获得SVR24且无肝细胞癌病史的丙型肝炎患者,分为训练集(n=484,ChuShikoku组)和验证集(n=585,Chubu组);所有患者在开始直接抗病毒药物治疗时及SVR24后每年两次接受超声监测肝细胞癌。

诊断标准与关键数值

  • ADRES评分基于SVR24时的三个参数:男性、FIB-4指数>3.25、甲胎蛋白>5.0 ng/mL,各计1分,总分0-3分;训练集预测肝细胞癌发生的c-index为0.835,验证集为0.899。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND AIM: To develop a scoring method using with common clinical data for predicting hepatocellular carcinoma (HCC) development after sustained virological response at 24 weeks (SVR24) after treatment with direct acting antivirals (DAAs), we retrospectively evaluated clinical features of patients who obtained SVR24.

METHODS: From October 2014 to December 2017, 1069 hepatitis C virus patients without a past history of HCC, who obtained SVR24 by DAAs at two different areas, were enrolled (the training [n = 484, ChuShikoku-group] and validation [n = 585, Chubu-group] sets). All were examined by ultrasonography as surveillance for HCC at the time of starting DAAs and twice a year after SVR24. We identified three parameters at SVR24, male gender, FIB-4 index > 3.25, and α-fetoprotein level > 5.0 ng/mL, as risk factors for HCC development and gave them point values, with the sum used as After DAAs Recommendation for Surveillance (ADRES) score.

RESULTS: In the ChuShikoku-group, the respective 1-/2-year rates for HCC incidence rates ADRES score 0 were 0.0%/0.0%, for a score 1 were 1.1%/2.1%, score 2 were 8.8%/15.9%, and score 3 were 17.1%/28.1%. On the other hand, those respective scores for the Chubu-group were 0.0%/0.0%, 0.0%/0.7%, 7.9%/10.6%, and 19.5%/not available. The c-index of the predictive value for HCC development in the training set after SVR24 was 0.835 while 0.899 in the validation set. Finally, those of the entire cohort were 0.0%/0.0%, 0.5%/1.6%, 8.4%/13.4%, and 18.0%/32.8%.

CONCLUSION: The present ADRES score was simple and easy to use and may be useful for predicting risk of HCC development in short term after reaching SVR24 by DAAs.

来源:J Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hiraoka A, Kumada T, Ogawa C, et al. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. J Gastroenterol Hepatol. 2018. PMID: 29996177. doi:10.1111/jgh.14378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。